Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J-RHYTHM Registry

Journal of the American Heart Association

Volumn 5, Issue 9, 2016, Pages

  Kodani, Eitaro ^a   Atarashi, Hirotsugu ^a   Inoue, Hiroshi ^b   Okumura, Ken ^c   Yamashita, Takeshi ^d   Otsuka, Toshiaki ^e   Tomita, Hirofumi ^f   Origasa, Hideki ^g  

^a NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^b Saiseikai Toyama Hospital   (Japan)

^c SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^d THE CARDIOVASCULAR INSTITUTE   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f HIROSAKI UNIVERSITY   (Japan)

^g UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Anticoagulation; Atrial fibrillation; Blood pressure; Hypertension; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; WARFARIN;

AGE DISTRIBUTION; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHA2DS2-VASC SCORE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE REGISTRY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; BLOOD PRESSURE; COMPLICATION; JAPAN; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR;

AGED; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; FEMALE; HEMORRHAGE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 85027373228     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.004075     Document Type: Article

References (31)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation, analysis and implications. Arch Intern Med. 1995;155:469-473.
3. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation-A report from the J-RHYTHM Registry. Circ J. 2011;75:1328-1333.
4. Akao M, Chun YH, Esato M, Abe M, Tsuji H, Wada H, Hasegawa K. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78:2166-2172.
5. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
6. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
7. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.
8. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
9. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999;53:1319-1327.
10. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173-180.
11. Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, Connolly SJ, Yusuf S, Ezekowitz MD. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial). Am J Cardiol. 2015;116:1204-1209.
12. Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015;4:e002015. doi:10.1161/JAHA.115.002015
13. Suzuki S, Yamashita T, Okumura K, Atarashi H, Akao M, Ogawa H, Inoue H. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J. 2015;79:432-438.
14. Inoue H, Atarashi H, Okumura K, Yamashita T, Origasa H, Kumagai N, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M, Saikawa T, Chishaki A. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. Am J Cardiol. 2014;113:957-962.
15. Tomita H, Okumura K, Inoue H, Atarashi H, Yamashita T, Origasa H. Assessment of risk factors for bleeding in Japanese patients with non-valvular atrial fibrillation receiving warfarin treatment: a subanalysis of the J-RHYTHM Registry. Int J Cardiol. 2015;201:308-310.
16. Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M, Saikawa T, Chishaki A. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J. 2013;77:2264-2270.
17. J-RHYTHM Registry Investigators. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan-Subanalysis of the J-RHYTHM Registry. Circ J. 2011;75:2357-2362.
18. 2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. Circ J. 2014;78:1593-1599.
19. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Use of warfarin in elderly patients with non-valvular atrial fibrillation-Subanalysis of the J-RHYTHM Registry. Circ J. 2015;79:2345-2352.
20. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Secondary prevention of stroke with warfarin in patients with non-valvular atrial fibrillation: subanalysis of the J-RHYTHM Registry. J Stroke Cerebrovasc Dis. 2016;25:585.
21. Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation-The J-RHYTHM Registry study design. J Cardiol. 2011;57:95-99.
22. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T. Target intensity of anticoagulation with warfarin in Japanese patients with valvular atrial fibrillation: subanalysis of the J-RHYTHM Registry. Circ J. 2015;79:325-330.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
24. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239.
25. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112-123.
26. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;45:907-913.
27. Lip GY, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752-759.
28. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34:2060-2065.
29. Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K, Koretsune Y, Sakamoto T, Iwade K, Yamamoto M, Takahashi JC, Minematsu K. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke. 2010;41:1440-1444.
30. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32:3-107.
31. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905.